24h
Current
Min
1347
Max
1362.5
Recommendations | Neutral |
---|---|
12 Months Forecast | +16.91 upside |
Next Earnings | 5 Feb 2025 |
---|---|
Next Dividend date | 10 Apr 2025 |
Next Ex Dividend date | 20 Feb 2025 |
By Acuity
33%
67%
103 / 392 Healthcare
Past performance is not a reliable indicator of future results.
13 Jan 2025, 07:14 UTC
GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion
DJ
Read
9 Jan 2025, 06:50 UTC
GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Billion, FT Says, Citing Sources
DJ
Read
15 Nov 2024, 10:28 UTC
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
DJ
Read
30 Oct 2024, 11:44 UTC
GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness -- Update
DJ
Read
30 Oct 2024, 07:50 UTC
GSK Profit Rises on HIV, Cancer Treatments But Sales Slip on Weak U.S. Vaccine Demand
DJ
Read
13 Jan 2025, 07:05 UTC
GSK Enters Agreement To Acquire IDRx, Inc. >GSK.LN
DJ
Read
13 Jan 2025, 07:00 UTC
GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Bln
DJ
Read
13 Jan 2025, 07:00 UTC
GSK to Make $1B Upfront Payment
DJ
Read
13 Jan 2025, 07:00 UTC
GSK to Buy IDRx for up to $1.15B
DJ
Read
13 Jan 2025, 07:00 UTC
GSK: Acquisition Adds to Portfolio in Gastrointestinal Cancers
DJ
Read
9 Jan 2025, 11:24 UTC
FDA Label Warning Threatens GSK's RSV Vaccine Sales -- Market Talk
DJ
Read
9 Jan 2025, 06:35 UTC
GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Bln, FT Says, Citing Sources
DJ
Read
15 Nov 2024, 13:08 UTC
Trump's RFK Pick Weighs on Vaccine Makers -- WSJ
DJ
Read
15 Nov 2024, 10:34 UTC
Vaccine Sector Sell-Off Looks Overdone -- Market Talk
DJ
Read
15 Nov 2024, 10:29 UTC
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
DJ
Read
7 Nov 2024, 11:53 UTC
Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com
DJ
Read
7 Nov 2024, 11:31 UTC
Moderna Earnings Beat Estimates. But Its Future Still Looks Uncertain. -- Barrons.com
DJ
Read
31 Oct 2024, 19:48 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update
DJ
Read
30 Oct 2024, 15:04 UTC
GSK's 3Q Results Are a Mixed Bag -- Market Talk
DJ
Read
30 Oct 2024, 08:22 UTC
GSK's Vaccine Weakness Is a Major Concern -- Market Talk
DJ
Read
30 Oct 2024, 07:18 UTC
GSK Reiterates Guidance As HIV And Cancer Drug Demand Offset Vaccine Weakness -- MarketWatch
DJ
Read
30 Oct 2024, 07:04 UTC
GSK PLC Expects to deliver Around Middle of Existing Annual Guidance Ranges
DJ
Read
30 Oct 2024, 07:03 UTC
GSK PLC 3Q EPS 1.4p
DJ
Read
30 Oct 2024, 07:02 UTC
GSK PLC Had Seen 2024 Sales Growth of 7% to 9%
DJ
Read
30 Oct 2024, 07:02 UTC
GSK PLC Issues Dividend of 15p
DJ
Read
30 Oct 2024, 07:01 UTC
GSK PLC Had Seen 2024 Core Earnings Per Share Growth of 10% to 12%
DJ
Read
30 Oct 2024, 07:01 UTC
GSK PLC Had Seen 2024 Core Operating Pft Growth Between 11% and 13%
DJ
Read
30 Oct 2024, 07:01 UTC
GSK PLC Backs 2024 View
DJ
Read
30 Oct 2024, 07:00 UTC
Analysts Saw GSK PLC 3Q Net Pft GBP1.78B
DJ
Read
30 Oct 2024, 07:00 UTC
Analysts Saw GSK PLC 3Q Turnover GBP8.00B
DJ
Read
By TipRanks
12 Months Forecast
Average 1,583 GBX 16.91%
High 2,355 GBX
Low 1,350 GBX
Based on 11 Wall Street analysts offering 12 month price targets forGlaxoSmithKline PLC - Dist in the last 3 months.
By TipRanks
Neutral
11 ratings
2
Buy
7
Hold
2
Sell
Based on 11 analysts giving stock ratings to GlaxoSmithKline PLC - Dist in the past 3 months.
By Acuity
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
$